Companies / Malaysia
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Pharmaniaga Ponders Strategy
May 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Because of losses incurred over the last twelve months, Malaysian generic medicine and healthcare company Pharmaniaga is reconsidering its operations in China. Escalating costs and less than acceptable sales have been attributed to changes in China's regulatory environment and maturation of distribution channels. BMI does not believe that this development accurately reflect the opportunities available in China and is of the view that perhaps Pharmaniaga's joint venture was not structured to its ultimate benefit, hence the losses in the last financial